Geoffrey Kline, DO
Cardiovascular Disease · Fort Worth, TXNPI 1497977490
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,289 and has fallen 56.6% since, to $560 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.
Across 155 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$707
- Medtronic$508
- Novartis$395
- Amgen$318
- Johnson & Johnson$244
- Boston Scientific$175
- plus $1K from 29 others
Across 37 payments — averaging $2064.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$37K
- Astrazeneca UK Limited$22K
- Boehringer Ingelheim International GmbH$7K
- Kowa Research Institute, Inc.$5K
- Boehringer Ingelheim Pharma GmbH & Co.kg$5K
What the payments were for
- Food & beverage$3,47597%
- Education$1133%
- Entertainment$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 25 | $707 |
| Medtronic | 12 | $508 |
| Novartis | 18 | $395 |
| Amgen | 17 | $318 |
| Johnson & Johnson | 12 | $244 |
| Boston Scientific | 5 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $149 |
| AstraZeneca | 9 | $137 |
| Sanofi-aventis U.S. LLC | 7 | $120 |
| E.r. Squibb & Sons, L.L.C. | 6 | $107 |
| Merck | 4 | $98 |
| Regeneron Healthcare Solutions, Inc. | 4 | $92 |
| Baxter Healthcare | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| UCB, Inc. | 2 | $39 |
| Bayer | 2 | $39 |
| Pfizer | 2 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| AbbVie | 1 | $27 |
| Medicomp Inc | 1 | $26 |
| Biotronik Inc. | 1 | $26 |
| Abbott | 1 | $22 |
| GE HealthCare | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Cardiovascular Systems Inc. | 1 | $12 |
| Hitachi Healthcare Americas Corp. | 1 | $11 |
How this compares
$3,599 in reported general payments places this provider in the 50th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $197,389 |
| EntrestoSacubitril/Valsartan | 85 | $84,073 |
| JardianceEmpagliflozin | 50 | $48,084 |
| FarxigaDapagliflozin Propanediol | 26 | $17,097 |
| XareltoRivaroxaban | 11 | $16,182 |
| Repatha SureclickEvolocumab | 12 | $10,385 |
| Metoprolol Succinate | 206 | $2,711 |
| Ranolazine ErRanolazine | 20 | $2,559 |
| Verapamil SrVerapamil Hcl | 27 | $1,469 |
| Atorvastatin Calcium | 133 | $1,193 |
| Carvedilol | 143 | $1,015 |
| Nifedipine ErNifedipine | 40 | $862 |
| Rosuvastatin Calcium | 75 | $818 |
| Midodrine Hcl | 13 | $805 |
| Lisinopril | 138 | $774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $31 | $197,389188 claims |
| NovartisEntresto | $395 | $84,07385 claims |
| Boehringer IngelheimJardiance | $16 | $48,08450 claims |
| AstraZenecaFarxiga | $137 | $17,09726 claims |
| Johnson & JohnsonXarelto | $244 | $16,18211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Fort Worth
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.